$1,417.54
+$43.84(+3.19%)
*Data last updated: 2026-11-01 06:13 (UTC+8)
As of 2026-11-01 06:13, Eli Lilly & Co. (LLY) is priced at $1,417.54, with a total market cap of $1.33T, a P/E ratio of 46.58, and a dividend yield of 0.00%. Today, the stock price fluctuated between $1,409.02 and $1,445.25. The current price is 0.60% above the day's low and 1.91% below the day's high, with a trading volume of 5.03M. Over the past 52 weeks, LLY has traded between $850.51 to $1,445.25, and the current price is -1.91% away from the 52-week high.
Key Stats
Yesterday's Close$1,373.70
Market Cap$1.33T
Volume5.03M
P/E Ratio46.58
Dividend Yield (TTM)0.00%
Dividend Amount$1.73
Net Income (FY)$20.64B
Revenue (FY)$65.17B
Earnings Date2027-02-03
EPS Estimate11.07
Revenue Estimate$24.40B
Shares Outstanding970.76M
Beta (1Y)0.453
Ex-Dividend Date2026-11-13
Dividend Payment Date2026-12-10
Introduction
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
SectorHealthcare
IndustryDrug Manufacturers - General
CEODavid A. Ricks
HeadquartersIndianapolis,IN,US
Official Websitehttps://www.lilly.com
Employees (FY)50.00K
Average Revenue (1Y)$1.30M
Net Income per Employee$412.80K
Learn
Gate Learn Articles
Eli Lilly (LLY) Stock Explained: Business Model, Growth Drivers, Valuation, and RisksEli Lilly (LLY) is a research-driven pharmaceutical company. The market closely watches LLY mainly for its anticipated growth from weight loss and diabetes medications. When assessing LLY stock, it is essential to consider its business model, product ramp-up, financial quality, valuation, and patent risks.2026-07-20

How to trade LLY stock on Gate? A step-by-step guide from searching to placing an orderWhen trading LLY stock on Gate, it is crucial to first verify the stock ticker LLY and the company entity, Eli Lilly and Company. Next, check the order type, trading hours, applicable fees, and funding details. Company research and platform execution should be managed independently.2026-07-20

Why is LLY stock valued so highly: risk, expectations, and long-term pricing logicLLY’s elevated valuation fundamentally represents the market’s forward pricing of anticipated growth and R&D realization. The key to matching this valuation is not about “cheapness,” but whether growth remains sustainable, competition escalates, and the pipeline delivers as projected.2026-07-20

Blogs
Eli Lilly (LLY) Q3 Revenue Grows 39% Year Over Year as Full-Year Guidance Rises: How Much Further Can the Stock Climb After Its Rally?Eli Lilly’s 2026 Q3 revenue came in at $24.397 billion, up 39% year over year, and the company raised its full-year revenue guidance to $91.0 billion–$92.0 billion. In this article, we break down the volume and price drivers, the Medicare coverage tailwind, and the competitive pressure from oral GLP-1s. We also assess the conditions needed for the stock’s post-guidance rally2026-10-30

Top Stocks to Watch This Week (Oct. 20–25): META, TSLA, WMT and MoreExplore seven U.S. stocks to watch this week, including META, TSLA, SPCX, WMT, LLY, HD, and PG, as earnings and sector rotation shape market sentiment.2026-10-20

Why Is Eli Lilly (LLY) Stock Volatile? After Q2 Revenue Surges 48%, Can the GLP-1 Supercycle Sustain a Decade of Growth?Eli Lilly’s Q2 Revenue Surges 48% Year-Over-Year, With GLP-1 Drugs Driving Over 60% of Total Income, Yet Stock Volatility Intensifies This Year. This article examines whether LLY can weather market cycles by analyzing its growth drivers, competitive landscape, and valuation pressures.2026-08-11

LLY FAQ
What's the stock price of Eli Lilly & Co. (LLY) today?
x
Eli Lilly & Co. (LLY) is currently trading at $1,417.54, with a 24h change of +3.19%. The 52-week trading range is $850.51–$1,445.25.
What are the 52-week high and low prices for Eli Lilly & Co. (LLY)?
x
What is the price-to-earnings (P/E) ratio of Eli Lilly & Co. (LLY)? What does it indicate?
x
What is the market cap of Eli Lilly & Co. (LLY)?
x
What is the most recent quarterly earnings per share (EPS) for Eli Lilly & Co. (LLY)?
x
Should you buy or sell Eli Lilly & Co. (LLY) now?
x
What factors can affect the stock price of Eli Lilly & Co. (LLY)?
x
How to buy Eli Lilly & Co. (LLY) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.






